We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Helius Medical Technologies Inc (HSDT) CAD0.001 A

Sell:$1.20 Buy:$1.30 Change: $0.12 (10.17%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.12 (10.17%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.12 (10.17%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Helius Medical Technologies, Inc. is a neurotech company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The Company's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The Company's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.

Contact details

642 Newtown Yardley Road
United States
+1 (215) 9446104

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.33 million
Shares in issue:
3.80 million
Health Care Equipment
United States
US dollar

Key personnel

  • Dane Andreeff
    President, Chief Executive Officer, Director
  • Jeffrey Mathiesen
    Chief Financial Officer, Treasurer
  • Joyce Laviscount
    Chief Operating Officer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.